<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508933</url>
  </required_header>
  <id_info>
    <org_study_id>0308202247</org_study_id>
    <nct_id>NCT04508933</nct_id>
  </id_info>
  <brief_title>Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and &quot;Typical&quot;ARDS Patients</brief_title>
  <official_title>Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and &quot;Typical&quot;ARDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University-Cerrahpasa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University-Cerrahpasa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Covid-19 also primarily affects endothelium that line up the alveoli. The resulting hypoxemia
      may differ from &quot;typical&quot; Acute Respiratory Distress Syndrome (ARDS) due to maldistribution
      of perfusion related to the ventilation. Thus, pathophysiology of Covid-19 ARDS is different,
      which requires different interventions than typical ARDS. The investigators will assess
      whether extravascular lung water index and permeability of the alveolar capillary differs
      from typical ARDS with transpulmonary thermodilution (TPTD) technique. Extravascular Lung
      Water Index (EVLWI) and Pulmonary Vascular Permeability Index (PVPI) will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extravascular Lung Water Index</measure>
    <time_frame>1 day</time_frame>
    <description>The amount of fluid accumulated in the lung measured by transpulmonary thermodilution (ml/kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary vascular permeability index</measure>
    <time_frame>1 day</time_frame>
    <description>Integrity of the alveolocapillary barrier measured by transpulmonary thermodilution</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Ventilation Perfusion Mismatch</condition>
  <condition>Pulmonary Edema</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Typical ARDS</arm_group_label>
    <description>ARDS due to non Covid19 causes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-ARDS</arm_group_label>
    <description>ARDS due to Covid19</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extravascular Lung Water Index</intervention_name>
    <description>Measurement of the EVLWI</description>
    <arm_group_label>C-ARDS</arm_group_label>
    <arm_group_label>Typical ARDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulmonary Vascular Permeability Index</intervention_name>
    <description>Measurement of the PVPI</description>
    <arm_group_label>C-ARDS</arm_group_label>
    <arm_group_label>Typical ARDS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with ARDS in the adult ICU that have a TPTD catheter inserted since 2018 will
        be eligible for recruitment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ARDS defined by Berlin Criteria longer than 24 hours

          -  Undergoing mechanical ventilation

          -  Noradrenaline demand &gt;0.1 mcg/kg/min

        Exclusion Criteria:

          -  Not meeting ARDS criteria

          -  Noninvasive mechanical ventilation

          -  ARDS resolved shorter than 24 hours

          -  Shock resolved
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yalım Dikmen, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olcay Dilken, MD</last_name>
    <phone>+90 554 737 87 09</phone>
    <email>olcaydilken@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul University-Cerrahpaşa</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Monnet X, Teboul JL. Transpulmonary thermodilution: advantages and limits. Crit Care. 2017 Jun 19;21(1):147. doi: 10.1186/s13054-017-1739-5. Review.</citation>
    <PMID>28625165</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 8, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University-Cerrahpasa</investigator_affiliation>
    <investigator_full_name>Olcay Dilken</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ards</keyword>
  <keyword>covid19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data available on reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

